M., Peitta, G., Simile, M
Toloza E, Hunt KK, Swisher SG , Rhoades K, McBride W, Lau R, Atha T, Pang S, Belldegrun A, Glaspy J, Economou J
Financial disclosure No financial support was received in relation to this article
The systemically acting intranasally administered biologics (proteins and peptides) under clinical investigation as enrolled at clinicaltrials.gov was listed by Rohrer et al
The standard dosing schedule starts at 2.5 mg weekly and escalates every four weeks: Weeks 14: 2.5 mg weekly (initiation dose to acclimate to GLP-1/GIP receptor activation) Weeks 58: 5 mg weekly Weeks 912: 7.5 mg weekly (optional intermediate step) Weeks 1316: 10 mg weekly Weeks 1720: 12.5 mg weekly (optional intermediate step) Week 21 onward: 15 mg weekly (maximum maintenance dose) Tirzepatide is injected subcutaneously just under the skin using a pre-filled pen or syringe
Weeks 4 to 8 bring the noticeable transition phase, where hunger gradually increases and food thoughts become more frequentthis is when intentional lifestyle choices become critical
